Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors

Pediatric Blood and Cancer

Volumn 54, Issue 3, 2010, Pages 369-376

  Von Hoff, Katja ^a   Hartmann, Wolfgang ^b   Von Bueren, André Oscar ^c,d   Gerber, Nicolas Ulrich ^a,c   Grotzer, Michael Andreas ^c   Pietsch, Torsten ^b   Rutkowski, Stefan ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anaplasia; C myc; Children; Large cell; Medulloblastoma

Indexed keywords

ADOLESCENT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER RISK; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; INFANT; MALE; MEDULLOBLASTOMA; METASTASIS; ONCOGENE C MYB; ONCOGENE C MYC; ONCOGENE MYC; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; AGE FACTORS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, TRKC; RISK FACTORS; RNA, MESSENGER;

EID: 76749111031     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22339     Document Type: Article

References (33)

1. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 1999;17:2127-2136.
2. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol 2005;23:7621-7631.
3. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
4. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006;24: 4202-4208.
5. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005;352:978-986.
6. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992;16:687-693.
7. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-865.
8. Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathological and genetic features. J Neurosurg 2001;95:82-88.
9. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22: 984-993.
10. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-449.
11. Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004;10:5482-5493.
12. Louis DN, Ohgaki H,Wiestler O, editors. et al.WHOClassification of tumours of the central nervous system. Lyon: IARC; 2007.
13. Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-2485.
14. Rutkowski S, von Bueren A, von HoffK, et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: Results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007;13:2651-2657.
15. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126: 540-544.
16. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89: 395-402.
17. Stearns D, Chaudhry A, Abel TW, et al. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-681.
18. Grotzer MA, Janss AJ, Phillips PC, et al. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 2000;212: 196-199.
19. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001; 7:2425-2433.
20. Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-719.
21. Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 2000;46:269-279.
22. Rutkowski S. Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma; www.clinicaltrials.gov; 2007.
23. Chang CH, Housepian EM, Herbert C, Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 1969;93:1351-1359.
24. Giangaspero F, Bigner SH, Kleihues P, et al. Medulloblastoma. In: Kleihues P, Cavenee WK, editors. World Health Organisation Classification of Tumours: Tumours of the Nervous System. Lyon: IARC Press; 2000. pp. 129-137.
25. Kunz F, Shalaby T, Lang D, et al. Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 2006;26:393-399.
26. McManamy CS, Lamont JM, Taylor RE, et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 2003;62:627-632.
27. Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: Results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 2005;63:711-716.
28. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: A Pediatric Oncology Group study. Cancer 2002;94:552-560.
29. Giangaspero F, Wellek S, Masuoka J, et al. Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol (Berl) 2006;112:5-12.
30. Pietsch T, Taylor MD, Rutka JT. Molecular pathogenesis of childhood brain tumors. J Neurooncol 2004;70:203-215.
31. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-442.
32. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
33. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004;10:7613-7620.